{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:35:13Z","timestamp":1781325313099,"version":"3.54.1"},"reference-count":34,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Primary tumor sidedness (left vs. right) has prognostic and predictive impact on anti-EGFR agent efficacy and thus management of metastatic colorectal cancer (mCRC). This analysis evaluates the relevance of primary tumor location (PTL) in RAS\/BRAF wild-type mCRC patients, when dividing the colorectal frame into six segments. This pooled analysis, performed on a single-patient basis of five randomized first-line therapy trials, evaluates the impact of exact PTL classification on baseline characteristics, prognosis and prediction of anti-EGFR antibody efficacy by chi-square and log-rank tests, the Kaplan\u2013Meier method, Cox and logistic regressions. The PTL was significantly associated with metastatic spread: liver (p = 0.001), lung (p = 0.047), peritoneal (p &lt; 0.001) and lymph nodes (p = 0.048). A multivariate analysis indicated an impact on anti-EGFR agent efficacy in terms of overall survival depending on the exact primary tumor location: from detrimental in caecal (HR 2.63), rather neutral effects in the ascending colon (HR 1.24), right flexure\/transverse colon (HR 0.99) and left flexure\/descending colon (HR 0.91) to clear benefit in sigmoid (HR 0.71) and rectal (HR 0.58) primaries. Exact primary tumor location affects anti-EGFR antibody efficacy in a rather continuous than a dichotomous fashion in RAS\/BRAF wild-type mCRC patients. This perspective might help to support clinical decisions when anti-EGFR antibodies are considered.<\/jats:p>","DOI":"10.3390\/cancers14030526","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T08:37:18Z","timestamp":1642754238000},"page":"526","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-3450","authenticated-orcid":false,"given":"Annabel H. S.","family":"Alig","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology, and Tumorimmunology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and HumboldtUniversit\u00e4t zu Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universit\u00e4t (LMU), 81377 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), DKFZ, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Geissler","sequence":"additional","affiliation":[{"name":"Hospital Karlsruhe, 76133 Karlsruhe, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Fischer von Weikersthal","sequence":"additional","affiliation":[{"name":"Klinikum St. Marien, 92224 Amberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Decker","sequence":"additional","affiliation":[{"name":"Onkologische Praxis, 88212 Ravensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Heinrich","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universit\u00e4t (LMU), 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swantje","family":"Held","sequence":"additional","affiliation":[{"name":"ClinAssess GmbH, 51379 Leverkusen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8101-3529","authenticated-orcid":false,"given":"Lena","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universit\u00e4t (LMU), 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8752-5827","authenticated-orcid":false,"given":"Laura E.","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universit\u00e4t (LMU), 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Moosmann","sequence":"additional","affiliation":[{"name":"Krankenhaus Barmherzige Br\u00fcder Regensburg, 93049 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Stahler","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Tumorimmunology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and HumboldtUniversit\u00e4t zu Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8969-6080","authenticated-orcid":false,"given":"Ivan","family":"Jelas","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Tumorimmunology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and HumboldtUniversit\u00e4t zu Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Kurreck","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Tumorimmunology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and HumboldtUniversit\u00e4t zu Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8843-9541","authenticated-orcid":false,"given":"Jobst C.","family":"von Einem","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Tumorimmunology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and HumboldtUniversit\u00e4t zu Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7838-6877","authenticated-orcid":false,"given":"Anke C.","family":"Reinacher-Schick","sequence":"additional","affiliation":[{"name":"St. Josef-Hospital, Klinikum der Ruhr-Universit\u00e4t Bochum, 44791 Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tannapfel","sequence":"additional","affiliation":[{"name":"Pathologisches Institut der Ruhr Universit\u00e4t Bochum, 44789 Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Giessen-Jung","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology & Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universit\u00e4t (LMU), 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-5801","authenticated-orcid":false,"given":"Sebastian","family":"Stintzing","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Tumorimmunology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and HumboldtUniversit\u00e4t zu Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik P.","family":"Modest","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Tumorimmunology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and HumboldtUniversit\u00e4t zu Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","article-title":"The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials","volume":"70","author":"Holch","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CAD.0000000000000041","article-title":"Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): Analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)","volume":"25","author":"Modest","year":"2014","journal-title":"Anti-Cancer Drug"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1001\/jamaoncol.2016.3797","article-title":"Prognostic and Predictive Relevance of Primary Tumor Location in Patients with RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials","volume":"3","author":"Tejpar","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ejca.2015.01.054","article-title":"Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis","volume":"51","author":"Pietrantonio","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1200\/PO.20.00050","article-title":"Intratumoral Transcriptome Heterogeneity Is Associated with Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial","volume":"4","author":"Fontana","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.18.02258","article-title":"Impact of Consensus Molecular Subtype on Survival in Patients with Metastatic Colorectal Cancer: Results From CALGB\/SWOG 80405 (Alliance)","volume":"37","author":"Lenz","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2020.07.003","article-title":"Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial","volume":"137","author":"Stahler","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1093\/annonc\/mdz387","article-title":"Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial","volume":"30","author":"Stintzing","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/gutjnl-2011-300865","article-title":"Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum","volume":"61","author":"Yamauchi","year":"2012","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1078-0432.CCR-17-2484","article-title":"Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes","volume":"24","author":"Loree","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejca.2010.09.022","article-title":"Phase III trial of irinotecan plus infusional 5-fluorouracil\/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer","volume":"47","author":"Schalhorn","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41416-020-01140-9","article-title":"FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: Final survival and per-protocol analysis of FIRE-3, a randomised clinical trial","volume":"124","author":"Heinemann","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.18.00052","article-title":"Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled StudyXELAVIRI (AIO KRK0110)","volume":"37","author":"Modest","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.19.01340","article-title":"FOLFOXIRI Plus Panitumumab as First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)","volume":"37","author":"Modest","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/ijc.26467","article-title":"The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial","volume":"131","author":"Modest","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2010.31.1936","article-title":"Cetuximab Plus Capecitabine and Irinotecan Compared with Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104-A Randomized Trial of the German AIO CRC Study Group","volume":"29","author":"Moosmann","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ijc.29807","article-title":"Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU\/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)","volume":"138","author":"Stahler","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/annonc\/mdr571","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: Mutated tumours in the randomised German AIO study KRK-0306","volume":"23","author":"Stintzing","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"E479","DOI":"10.1016\/S1470-2045(16)30269-8","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): A post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial","volume":"17","author":"Stintzing","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2017.03.023","article-title":"Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: Analysis of the FIRE-3 (AIO KRK-0306) study","volume":"79","author":"Stintzing","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lee, K.H., Chen, W.S., Jiang, J.K., Yang, S.H., Wang, H.S., Chang, S.C., Lan, Y.T., Lin, C.C., Lin, H.H., and Huang, S.C. (2021). The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle\/low rectum and the left-sided colon. Br. J. Cancer.","DOI":"10.1038\/s41416-021-01470-2"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e000489","DOI":"10.1136\/esmoopen-2019-000489","article-title":"Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study","volume":"4","author":"Cremolini","year":"2019","journal-title":"ESMO Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clcc.2014.12.011","article-title":"Role of First-Line Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials","volume":"14","author":"Khattak","year":"2015","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/1078-0432.CCR-12-1515","article-title":"Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials","volume":"19","author":"Giessen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1200\/JCO.2012.42.8532","article-title":"Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated with Cetuximab","volume":"31","author":"Piessevaux","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.ejca.2015.03.026","article-title":"Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer","volume":"51","author":"Douillard","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1158\/1078-0432.CCR-20-2748","article-title":"Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials","volume":"26","author":"Stahler","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/jamaoncol.2017.3168","article-title":"Association of Tumor HER3 Messenger RNA Expression with Panitumumab Efficacy in Advanced Colorectal Cancer","volume":"4","author":"Seligmann","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","article-title":"PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1078-0432.CCR-18-1324","article-title":"Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer","volume":"25","author":"Grisoni","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamaoncol.2015.6065","article-title":"Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients with RAS Wild-Type Advanced Colorectal Cancer","volume":"2","author":"Seligmann","year":"2016","journal-title":"JAMA Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/526\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:05:14Z","timestamp":1760133914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030526"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030526","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]}}}